Raymond James Financial’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
KCM
Raymond James Financial's BEAM Position: Q3 2026 in Review
Raymond James Financial reduced its Beam Therapeutics (BEAM) stake by 11% in Q3 2026, selling an estimated $120K and leaving 34,451 shares worth $842K. The position accounts for ﹤0.01% of the portfolio, ranked #4162.
Raymond James Financial first reported a position in BEAM in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.33M in Q2 2026. 264 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.
- Raymond James Financial held 34,451 shares of Beam Therapeutics worth $842K as of Q3 2026.
- Raymond James Financial sold 4,295 Beam Therapeutics shares in Q3 2026, an estimated $120K.
- Beam Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #4162 holding.
- Raymond James Financial first reported a position in Beam Therapeutics in Q4 2024 and has held it in 8 quarters since.
- Raymond James Financial's Beam Therapeutics position peaked at $1.33M in Q2 2026.
- 264 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.
Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.